Newswise Focus Channel: Cancer Center Featured Story 2

NCCN Announces Funding for a Prostate Cancer Research Project

National Comprehensive Cancer Network(r) (NCCN(r)) — Wed, 11 Dec 2024 08:00:55 EST

The NCCN Oncology Research Program (ORP) announces funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi).

MD Anderson's Lauren Averett Byers Receives TAMEST O'Donnell Award for Seminal Contributions to Lung Cancer Research

University of Texas MD Anderson Cancer Center — Wed, 11 Dec 2024 08:00:00 EST

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST). The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer (SCLC), which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.

HPV Genotype-Specific Prevalence and Infection Risks: A 10-Year Population-Based Study From the United States

University of New Mexico Comprehensive Cancer Center — Tue, 10 Dec 2024 14:20:12 EST

MD Anderson and AmMax Bio Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

University of Texas MD Anderson Cancer Center — Tue, 10 Dec 2024 08:00:59 EST

MD Anderson and AmMax Bio announced agreements to develop and advance AmMax's AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease.

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

University of Texas MD Anderson Cancer Center — Mon, 09 Dec 2024 20:00:38 EST

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH

Roswell Park Comprehensive Cancer Center — Mon, 09 Dec 2024 19:30:00 EST

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.

KU Medical Center Evaluating Smoking-Cessation Interventions for Black Adults in a Five-State Study

University of Kansas Cancer Center — Mon, 09 Dec 2024 14:55:28 EST

The University of Kansas Medical Center is partnering with the University of Wisconsin Center for Tobacco Research and Intervention to determine what treatments work best to help Black people to quit smoking. Their research is funded with a $10 million award from the Patient-Centered Outcomes Research Institute.

Heavy Metal Gut: A $1.9 million Study

University of New Mexico Comprehensive Cancer Center — Mon, 09 Dec 2024 11:30:41 EST

Julie In, PhD, received a $1.9 million grant from the National Institute of Environmental Health Sciences to study the impact of uranium on the cells that line the intestines.

Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows

Roswell Park Comprehensive Cancer Center — Sun, 08 Dec 2024 16:30:07 EST

Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.

Multi-Center Study Shows Education Level, Income Impact Access to Stem Cell Transplantation for Acute Myeloid Leukemia Patients

Fred Hutchinson Cancer Center — Sun, 08 Dec 2024 11:10:31 EST

Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive a allogeneic hematopoietic stem cell transplant for acute myeloid, however, if they can access the treatment, are equally likely to benefit from transplant as patients with more education and higher income, according to a new study from Fred Hutch Cancer Center presented at the annual meeting of the American Society of Hematology.

Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias

Roswell Park Comprehensive Cancer Center — Sat, 07 Dec 2024 19:00:24 EST

A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates -- FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.

NCCN Hosts Patient Advocacy Summit on Improving Access to Accurate Health Information

National Comprehensive Cancer Network(r) (NCCN(r)) — Fri, 06 Dec 2024 14:00:09 EST

NCCN hosts a Patient Advocacy Summit bringing together leading experts to promote strategies and best practices for improving cancer care, focused on practice and policy solutions for sharing accurate, evidence-based health information with patients and caregivers.

Tip Sheet: New Insights on RSV and Malaria, Metastatic Breast Cancer Resources for Patients -- and Fred Hutch at ASH

Fred Hutchinson Cancer Center — Thu, 05 Dec 2024 09:00:27 EST

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.

MD Anderson Research Highlights: ASH 2024 Special Edition

University of Texas MD Anderson Cancer Center — Wed, 04 Dec 2024 12:00:04 EST

The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, providing new insights and advances in hematological malignancies and diseases. All ASH content from MD Anderson can be found at MDAnderson.org/ASH.

Cancer Risk Declines in Old Age, New MSK Research Helps Explain Why

Memorial Sloan Kettering Cancer Center — Wed, 04 Dec 2024 11:25:19 EST

A new laboratory study provides evidence about how advanced age can be protective against cancer -- with implications for treating patients in different age groups.

MSK Awards and Appointments November 2024

Memorial Sloan Kettering Cancer Center — Wed, 04 Dec 2024 10:00:00 EST

NEW YORK, December 4, 2024 - Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:

NCCN Awards Grants to Improve Care for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Comprehensive Cancer Network(r) (NCCN(r)) — Wed, 04 Dec 2024 08:00:02 EST

The NCCN Oncology Research Program (ORP) announces the awarding of new quality improvement research grants aimed at advancing care for patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Fred Hutch at ASH: Plenary Session on Socioeconomic Barriers to Transplant, New Leukemia Treatments and Phasing Out 'Cumbersome' Urine Test

Fred Hutchinson Cancer Center — Tue, 03 Dec 2024 14:45:18 EST

The of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme of many presentations by Fred Hutch Cancer Center experts, including: Meta-analyses show socioeconomic factors limit access to transplants and clinical trials, highlighting strategies to overcome barriers.

Tomorrow's Promise, Today's Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment

Roswell Park Comprehensive Cancer Center — Mon, 02 Dec 2024 15:50:33 EST

Roswell Park President and CEO Candace S. Johnson, PhD, today introduced the cancer center's first Physician in Chief -- and the slate of experts appointed to tackle the most pressing opportunities and challenges related to cancer treatment, outcomes and delivery of care.

Transcription Factors ASCL1 and OLIG2 Drive Glioblastoma Initiation and Co-Regulate Tumor Cell Types and Migration

University of New Mexico Comprehensive Cancer Center — Mon, 02 Dec 2024 12:45:14 EST